0000797542-14-000003.txt : 20141121 0000797542-14-000003.hdr.sgml : 20141121 20141121165223 ACCESSION NUMBER: 0000797542-14-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20141121 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141121 DATE AS OF CHANGE: 20141121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZAXIS INTERNATIONAL INC CENTRAL INDEX KEY: 0000797542 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 680080601 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15746 FILM NUMBER: 141243609 BUSINESS ADDRESS: STREET 1: 7 JABOTINSKI STREET STREET 2: SUITE 5709 CITY: RAMAT GAN STATE: L3 ZIP: 52520 BUSINESS PHONE: 97236116720 MAIL ADDRESS: STREET 1: 7 JABOTINSKI STREET STREET 2: SUITE 5709 CITY: RAMAT GAN STATE: L3 ZIP: 52520 FORMER COMPANY: FORMER CONFORMED NAME: INFERGENE CO DATE OF NAME CHANGE: 19920703 8-K 1 zxsi8k.htm FORM 8-K zxsi

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K
___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): November 21, 2014

 

ZAXIS INTERNATIONAL INC.
(Exact Name of Registrant as Specified in its Charter)

 

Commission File No.: 0-15476

 

Delaware 68-0080601
(State of Incorporation) (I.R.S. Employer Identification No.)
   
7 Jabotinski Street, Suite 5709, Ramat Gan, Israel 52520
(Address of Principal Executive Offices) (ZIP Code)

 

Registrant's Telephone Number, including area code: (972) 3611-6720

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 21, 2014, the Registrant's Board of Directors appointed Jehuda Maimon, age 56, as Chief Executive Officer, Chief Financial Officer and Director of the Registrant. Mr. Maimon, a certified tax advisor in Israel. During the past five years, Mr. Maimon has served in the following positions: (i) Since January 2014, he has been a director and general manager of WideMed Ltd., a public Israeli company listed on the Tel-Aviv Stock Exchange (the "TASE"). WideMed is engaged in the growing bio-medical signal diagnostics and treatment market. Mr. Maimon's responsibilities include evaluation and analysis of potential merger and acquisition candidates and strategic business initiatives; and (ii) From 2009 to the present, Mr. Maimon had been vice president of finance and general manager of Zeusport Ltd., a private company, the largest Sports Club in Israel. Since 1981, Mr. Maimon has been an active investor real estate, both in Israel and Europe. Mr. Maimon previously served as a financial and business consultant to Alonai Meitar Ltd. and Tshua 10 Ltd., both private companies engaged in the real estate investment business, principally in Eastern Europe.

Mr. Maimon is a graduate of College of Management-Academic Studies, Rishon LeZion, Israel, the largest College in Israel.

On November 21, 2014, in connection with the appointment of Mr. Maimon, the Registrant's Board of Directors accepted the resignation of Ivo Heiden as CEO, CFO and Director of the Registrant. Mr. Heiden resigned as an officer and director in order to pursue other business opportunities and had no disagreements with the Registrant's operations, policies or practices.

Mr. Heiden's letter of resignation dated November 21, 2014, is attached as Exhibit 17.1 hereto.

Item 9.01 Financial Statements and Exhibits

(b) The following documents are filed as exhibits to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.

 Description
17.1 Letter of Resignation of Ivo Heiden, dated November 21, 2014, filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Jehuda Maimon
CEO
Jehuda Maimon
  Date: November 21, 2014

 

 EX-17 2 exh17_1.htm EXHIBIT 17.1

Exhibit 17.1

November 21, 2014

Board of Directors
Zaxis International Inc.
6230 Wilshire Blvd., Suite 46
Los Angeles, CA 90048

Re: Letter of Resignation

Gentlemen:

I hereby resign as Chief Executive Officer, Chief Financial Officer and a director of Zaxis International Inc. (the "Company"), effective immediately. The reason for my resignation is to permit me to pursue other business interests.

I have had no disagreements with the Company's operations, policies or practices.

Yours truly,

/s/ Ivo Heiden
Ivo Heiden